Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review.
adverse drug events
exocrine pancreatic insufficiency
malnutrition
neuroendocrine tumors
somatostatin analogs
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
revised:
06
04
2024
received:
31
01
2024
accepted:
16
05
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
24
5
2024
Statut:
aheadofprint
Résumé
Neuroendocrine tumors (NETs) are a group of well-differentiated heterogeneous neoplasms characterized by slow progression and distinct clinical and biological behavior. In the majority of patients with NET, first-line treatment is represented by somatostatin analogs (SSAs) that, despite being drugs with high tolerability (even at high doses) and providing to carcinoid symptoms control and anti-proliferative effects, may present some side effects, with potential impact on quality of life and nutritional status. The most frequent side effects are represented by gastrointestinal events in particular alterations in bowel habits (diarrhea and constipation), abdominal pain, exocrine pancreatic insufficiency, and cholelithiasis. Considering the relative rarity of NETs, literature about frequency and standard clinical management of adverse events SSA-related is still lacking and heterogeneous. The aim of this review is to arm gastroenterologists and other physicians treating NET patients with essential knowledge on the side effects of SSAs. By identifying and managing these adverse events early, healthcare professionals can offer optimal care, avert foreseeable complications, and ensure the best outcomes for patients. Without such early recognition, there is a risk of diminishing the patient's quality of life and their ability to sustain treatment over time.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Dasari A, Shen C, Halperin D et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017; 3: 1335.
Rindi G, Mete O, Uccella S et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr. Pathol. 2022; 33: 115–154.
Panzuto F, Merola E, Pavel ME et al. Stage IV gastro‐entero‐pancreatic neuroendocrine neoplasms: a risk score to predict clinical outcome. Oncologist 2017; 22: 409–415.
Cives M, Strosberg J, Pelle' E, Strosberg J. Emerging treatment options for gastroenteropancreatic neuroendocrine tumors. J. Clin. Med. 2020; 9: 3655.
Rinke A, Müller HH, Schade‐Brittinger C et al. Placebo‐controlled, double‐blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 2009; 27: 4656–4663.
Caplin ME, Pavel M, Ćwikła JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 2014; 371: 224–233.
Faggiano A. Long‐acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20‐year‐old story. J. Endocrinol. Invest. 2024; 47: 35–46.
Jimenez‐Fonseca P, Carmona‐Bayonas A, Lamarca A et al. External validity of somatostatin analogs trials in advanced neuroendocrine neoplasms: the GETNE‐TRASGU study. Neuroendocrinology 2021; 112: 88–100.
Wu Q, Chen B, Yan G, Yang Z, Xiong L, He J. A systematic review and meta‐analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors. Onco. Targets. Ther. 2018; 11: 7655–7668.
Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long‐acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT‐2): a randomised, placebo‐controlled, phase 3 study. Lancet 2011; 378: 2005–2012.
Whyand T, Bouvier C, Davies P. Prevalence of self‐reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues. Br. J. Nurs. 2018; 27: 738–744.
Pusceddu S, Rossi RE, Torchio M et al. Differential diagnosis and management of diarrhea in patients with neuroendocrine tumors. J. Clin. Med. 2020; 9: 2468.
Grozinsky‐Glasberg S, Davar J, Hofland J et al. European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J. Neuroendocrinol. 2022; 34.
Chang L, Chey WD, Imdad A et al. American Gastroenterological Association‐American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology 2023; 164: 1086–1106.
Lamarca A, McCallum L, Nuttall C et al. Somatostatin analogue‐induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Rev. Gastroenterol. Hepatol. 2018; 12: 723–731.
Saif MW, Larson H, Kaley K, Shaib W. Chronic octreotide therapy can induce pancreatic insufficiency: a common but under‐recognized adverse effect. Expert Opin. Drug Saf. 2010; 9: 867–873.
Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. Pancreatology 2020; 20: 875–879.
Hall LA, Powell‐Brett S, Thompson O et al. Casting a wider NET: pancreatic exocrine insufficiency induced by somatostatin analogues among patients with neuroendocrine tumours? Cancers 2023; 15: 1933. https://doi.org/10.3390/cancers15071933
Vanga RR, Tansel A, Sidiq S, El‐Serag HB, Othman MO. Diagnostic performance of measurement of fecal elastase‐1 in detection of exocrine pancreatic insufficiency: systematic review and meta‐analysis. Clin. Gastroenterol. Hepatol. 2018; 16: 1220–1228.e4.
Whitcomb DC, Buchner AM, Forsmark CE. AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review. Gastroenterology 2023; 165: 1292–1301.
de la Iglesia D, Avci B, Kiriukova M et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta‐analysis. United Eur. Gastroenterol. J. 2020; 8: 1115–1125.
Panzuto F, Magi L, Rinzivillo M. Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia. Expert Opin. Drug Saf. 2021; 20: 383–386.
Ahrendt SA, McGuire GE, Pitt HA, Lillemoe KD. Why does somatostatin cause gallstones? Am. J. Surg. 1991; 161: 177–183.
Turner H, Lindsell D, Vadivale A, Thillainayagam A, Wass J. Differing effects on gall‐bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur. J. Endocrinol. 1999: 590–594.
Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 1997; 79: 830–834.
Attanasio R, Mainolfi A, Grimaldi F et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J. Endocrinol. Invest. 2008; 31: 704–710.
Brighi N, Lamberti G, Maggio I et al. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Dig. Liver Dis. 2019; 51: 689–694.
European Association for the Study of the Liver. EASL clinical practice guidelines on the prevention, diagnosis and treatment of gallstones. J. Hepatol. 2016; 65: 146–181.
Brighi N, Panzuto F, Modica R et al. Biliary stone disease in patients with neuroendocrine tumors treated with somatostatin analogs: a multicenter study. Oncologist 2019; 25: 259–265.
Norlén O, Hessman O, Stålberg P, Åkerström G, Hellman P. Prophylactic cholecystectomy in midgut carcinoid patients. World J. Surg. 2010; 34: 1361–1367.
Alonso‐Gordoa T, Manneh R, Grande E, Molina‐Cerrillo J. High‐dose somatostatin analogs for the treatment of neuroendocrine neoplasms: where are we now? Curr. Treat. Options Oncol. 2022; 23: 1001–1013.
Panzuto F, Ricci C, Rinzivillo M et al. The antiproliferative activity of high‐dose somatostatin analogs in gastro‐entero‐pancreatic neuroendocrine tumors: a systematic review and meta‐analysis. J. Clin. Med. 2022; 11: 6127.
Pavel M, Ćwikła JB, Lombard‐Bohas C et al. Efficacy and safety of high‐dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur. J. Cancer 2021; 157: 403–414.
Strosberg J, El‐Haddad G, Wolin E et al. Phase 3 trial of 177Lu‐Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 2017; 376: 125–135.
Singh S, Halperin DM, Myrehaug S et al. [177Lu]Lu‐DOTA‐TATE in newly diagnosed patients with advanced grade 2 and grade 3, well‐differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER‐2 study. J Clin Oncol 2024; 42: abstr LBA588. https://doi.org/10.1200/JCO.2024.42.3_suppl.LBA588.
Lamberti G, Faggiano A, Brighi N et al. Nonconventional doses of somatostatin analogs in patients with progressing well‐differentiated neuroendocrine tumor. J. Clin. Endocrinol. Metabol. 2019; 105: 194–200.
Laing E, Gough K, Krishnasamy M, Michael M, Kiss N. Prevalence of malnutrition and nutrition‐related complications in patients with gastroenteropancreatic neuroendocrine tumours. J. Neuroendocrinol. 2022; 34: e13116.
Maasberg S, Knappe‐Drzikova B, Vonderbeck D et al. Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasia. Neuroendocrinology 2017; 104: 11–25.
Herrera‐Martínez Y, Alzas Teomiro C, León Idougourram S et al. Sarcopenia and ghrelin system in the clinical outcome and prognosis of gastroenteropancreatic neuroendocrine neoplasms. Cancer 2022; 14: 111.
Sebastian‐Valles F, Sánchez de la Blanca Carrero N, Rodríguez‐Laval V et al. Impact of change in body composition during follow‐up on the survival of GEP‐NET. Cancer 2022; 14: 5189.
Yadegarfar G, Friend L, Jones L et al. Validation of the EORTC QLQ‐GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br. J. Cancer 2013; 108: 301–310.
Gosain R, Gupta M, Roy AM, Strosberg J, Glaser KM, Iyer R. Health‐related quality of life (HRQoL) in neuroendocrine tumors: a systematic review. Cancer 2022; 14: 1428.
Rinke A, Neary MP, Eriksson J, Hunger M, Doan T, Karli D, Arnold R. Health‐related quality of life for long‐acting octreotide versus placebo in patients with metastatic midgut neuroendocrine tumors in the Phase 3 PROMID trial. Neuroendocrinology 2019; 109: 141–151.
Sorbye H, Meyer LS, Mordal KE, Myhre S, Thiis‐Evensen E. Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small‐intestinal neuroendocrine tumours. Health Qual. Life Outcomes 2020; 18: 188.
Adams JR, Ray D, Willmon R, Pulgar S, Dasari A. Living with neuroendocrine tumors: assessment of quality of life through a mobile application. JCO Clin. Cancer Inform. 2019; 3: 1–10.
La Salvia A, Modica R, Rossi RE et al. Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists. Cancer Treat. Rev. 2023; 117: 102560.